stoxline Quote Chart Rank Option Currency Glossary
Rallybio Corporation (RLYB)
2.075  0.275 (15.28%)    02-27 14:44
Open: 1.8
High: 2.08
Volume: 107,729
Pre. Close: 1.8
Low: 1.8
Market Cap: 78(M)
Technical analysis
2024-02-27 2:16:53 PM
Short term     
Mid term     
Targets 6-month :  2.41 1-year :  2.82
Resists First :  2.06 Second :  2.41
Pivot price 1.77
Supports First :  1.54 Second :  1.22
MAs MA(5) :  1.83 MA(20) :  1.66
MA(100) :  2.52 MA(250) :  4.45
MACD MACD :  0 Signal :  -0.1
%K %D K(14,3) :  74 D(3) :  68.2
RSI RSI(14): 61
52-week High :  9.87 Low :  1.22
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ RLYB ] has closed above the upper band by 5.3%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 61.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.88 - 1.89 1.89 - 1.91
Low: 1.71 - 1.72 1.72 - 1.73
Close: 1.78 - 1.8 1.8 - 1.82
Company Description

Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.

Headline News

Mon, 26 Feb 2024
Rallybio to Present at the TD Cowen 44th Annual Health Care Conference - Yahoo Finance

Wed, 07 Feb 2024
Rallybio Corp (RLYB) is lower by 2.58% Wednesday In Premarket Trading - InvestorsObserver

Wed, 07 Feb 2024
Rallybio (NASDAQ:RLYB) Price Target Cut to $8.00 - MarketBeat

Wed, 07 Feb 2024
Rallybio Announces Workforce Reduction and Restructuring Costs - - TipRanks

Tue, 06 Feb 2024
Rallybio shares jump 13% on restructuring, cash runway extension (NASDAQ:RLYB) - Seeking Alpha

Tue, 06 Feb 2024
Rallybio Announces Portfolio Prioritization and Provides Corporate Update - Business Wire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 38 (M)
Shares Float 17 (M)
Held by Insiders 5.5 (%)
Held by Institutions 87.2 (%)
Shares Short 753 (K)
Shares Short P.Month 678 (K)
Stock Financials
EPS -1.79
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.26
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -33.9 %
Return on Equity (ttm) -55.3 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.98
Qtrly Earnings Growth 0 %
Operating Cash Flow -64 (M)
Levered Free Cash Flow -39 (M)
Stock Valuations
PE Ratio -1.15
PEG Ratio 0
Price to Book value 0.62
Price to Sales 0
Price to Cash Flow -1.22
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android